TPM3 and cancer: Shortly thereafter, in 2018, larotrectinib received accelerated approval by the FDA for the treatment of TRK fusion-positive cancers of any type and any age.* This was followed in 2019 by the approval of entrectinib for TRK fusion-positive cancers in Japan and the US.